Stryker (SYK) DIvidends Date & History

Key Takeaways

• SYK pays a quarterly dividend of $0.88 per share, or $3.52 annually, for a dividend yield of roughly 1%.
• The company has increased its dividend for 32 consecutive years, making it a consistent dividend growth stock.
• The payout ratio of about 36% of earnings leaves ample room for continued dividend increases.
• Stryker's yield is below the healthcare sector median, so it appeals more to dividend growth investors than to income-focused investors.
• The five-year dividend growth rate of approximately 7.9% outpaces many peers in the medical device industry.

Dividend Overview

Stryker Corporation, a global medical technology leader in orthopedics, surgical equipment, and neurotechnology, maintains a disciplined quarterly dividend policy. As of late 2026, the company pays $0.88 per share each quarter, translating to an annual dividend of $3.52 per share. Based on the current share price, that equates to a dividend yield of approximately 1%, which is modest by income standards.

Stryker is best characterized as a dividend growth stock rather than a high-yield stock. The company has prioritized steady, predictable increases over a large current payout, a strategy consistent with its broader focus on reinvesting earnings into research, innovation, and acquisitions. Dividend payments are made quarterly, with recent ex-dividend dates falling at the end of March, June, September, and December, and payments following roughly one month later.

Dividend History and Growth

Stryker's dividend record reflects remarkable consistency. The company has raised its payout for 32 consecutive years, a streak that places it among the more dependable dividend growers in the healthcare sector. Its most recent increase, announced in December 2025, lifted the quarterly dividend from $0.84 to $0.88 per share, a roughly 4.8% boost.

The longer-term trajectory shows steady compounding. Annual dividends per share rose from about $2.59 in 2021 to $2.84 in 2022, $3.05 in 2023, $3.24 in 2024, and roughly $3.40 in 2025. Stryker's five-year dividend growth rate stands near 7.9%, while its most recent trailing twelve-month increase was approximately 5%. This pattern of regular, mid-single-digit annual raises reflects management's long-term commitment to returning value to shareholders without sacrificing growth.

Dividend Sustainability and Payout Ratio

Stryker's dividend appears highly sustainable. The company's payout ratio—the share of earnings distributed as dividends—is roughly 36% to 40% on a trailing twelve-month basis, and its cash payout ratio, which measures dividends against free cash flow, is similarly low at about 32%. These figures indicate that the company retains the majority of its earnings and cash flow to fund operations, research, and strategic initiatives.

This conservative payout posture gives Stryker substantial flexibility to maintain and grow its dividend even during periods of softer earnings. The company's strong free cash flow generation, diversified product portfolio, and relatively modest debt burden relative to earnings further support the reliability of its payments. Because earnings comfortably cover the dividend multiple times over, the risk of a dividend cut is considered low, and the likelihood of continued annual increases remains high.

Dividend Compared to Industry Peers

Within the medical device and healthcare equipment industry, Stryker's dividend yield is on the lower end of the spectrum. The healthcare sector median yield typically exceeds 1.5%, and several large-cap peers offer meaningfully higher current income. For example, MDT (Medtronic) and JNJ (Johnson & Johnson) each carry yields of roughly 3%, while ABT (Abbott Laboratories) offers a yield around 2%.

However, Stryker compensates for its modest yield with a faster dividend growth rate and a lower payout ratio. Compared with slower-growing, higher-yielding peers, Stryker's combination of a roughly 7.9% five-year dividend growth rate and a payout ratio near 36% suggests greater capacity for future increases. This positions the company as a growth-oriented dividend payer rather than a pure income vehicle.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market efficiently. It enables users to scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending names, and breakout candidates far more quickly than manual screening. For investors seeking dependable dividend growers or comparing yield profiles across industries, the AI Screener offers a practical starting point for building a focused watchlist.

Is This Stock Attractive for Dividend Investors?

Stryker is most suitable for dividend growth investors and long-term investors who prioritize steadily rising income over high current yield. Its 32-year streak of dividend increases, low payout ratio, and roughly 7.9% five-year dividend growth rate make it a compelling candidate for those building a compounding income stream over time. Because the yield is only around 1%, the stock is less appropriate for income-focused investors seeking substantial cash flow today, such as retirees depending on dividends for immediate expenses.

Conservative investors may also find appeal in Stryker's financial stability and diversified medical technology business, which generates resilient demand across economic cycles. Still, prospective investors should weigh the modest yield, valuation, and growth expectations against their own objectives. Stryker functions best as a long-term holding where dividend growth, rather than current payout, drives total shareholder return.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations